US OptionsDetailed Quotes
RIGL250117C14000
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest14.00Strike Price0.00Turnover150.43%IV-13.85%PremiumJan 17, 2025Expiry Date2.25Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8031Delta0.0858Gamma6.13Leverage Ratio-0.0727Theta0.0018Rho4.92Eff Leverage0.0060Vega
Rigel Pharmaceuticals Stock Discussion
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
103
32
15
$Rigel Pharmaceuticals (RIGL.US)$ Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289
WSJ· 08:36
WSJ· 08:36
1
$Rigel Pharmaceuticals (RIGL.US)$
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Thursday, 9th January at 8:05 am
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, ...
Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Thursday, 9th January at 8:05 am
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS). R2891, ...
2
$Rigel Pharmaceuticals (RIGL.US)$
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that the FDA has granted Fast Track designation to R289 for treating patients with previously-treated transfusion dependent lower-risk myelodysplastic syndrome (LR-MDS). R289, a dual inhibitor of IRAK1 and IRAK4, is currently being evaluated in a Phase 1b study. The Fast Track designation may provide benefits including more freque...
1
$Rigel Pharmaceuticals (RIGL.US)$ Reuters· 1 min ago
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk Mds
1
1
$Rigel Pharmaceuticals (RIGL.US)$ waiting for $50+
No comment yet
151158967 : Thank you, @Jaguar8 . Your hard work is appreciated!
103687630 : I think, what do you think of ONDS? There was good news on Wednesday but it went down. Do you think there is a chance for a rebound?
Jaguar8 OP 103687630 : I didn’t choose it because it didn’t specify how much is the contract.
103687630 Jaguar8 OP : Okay, thank you for your reply
70761249 : Can VERI make a breakthrough in the short term? The recent wildfires in Southern California are really heartbreaking, causing significant disappointment in the credibility of the media and government.
View more comments...